Task-orientated visual satisfaction evaluation could help lens design selection

Article

Using a task-orientated visual satisfaction evaluation has potential to help in lens design selection and predicting wearing success.

Using a task-orientated visual satisfaction evaluation has potential to help in lens design selection and predicting wearing success, according to a paper in Journal of Optometry.

Dr Joan Gispets et al., University Vision Centre, Universitat Politècnica de Catalunya, Terrassa, Barcelona, Spain, completed a longitudinal prospective, cross-over, double-masked study on 22 presbyopic patients were randomly and alternatively fitted with two types of multifocal lenses.

The patients followed two 14-day trial periods, after which overall satisfaction was evaluated. The wearing success of the lens was assessed via the percentage of subjects choosing to continue wearing a multifocal lens and by the total number of subjects continuing to wear the lenses six months later. Habitual tasks were identified by observation distance, visual demand level and time allocation.

Visual satisfaction was affected by viewing distance and visual demand level. It decreased when tasks required higher visual demands involving near and far distance vision, compared to intermediate vision or a combination of near and far vision. It was found that the main reason for patient discontinuation of multifocal lenses was due to insufficient quality of vision.

Finally, 78% of the patients included in the study chose to continue wearing the lenses, with 1 patient deciding to wear them daily 6 months after study completion. The investigation suggests that a task-orientated visual satisfaction evaluation could be beneficial towards the design selection of a patient's lens and the determination of wearing success.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.